Company
Penumbra
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
68
510(k), De Novo and PMA
Device trials
31
As lead sponsor, any status
Adverse event reports
449
Received Nov 1, 2025 to Nov 20, 2026
Recall records
12
One per recalled product
Penumbra is on our public-company list (ticker PEN). Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.
Listed
PEN
NYSE · Penumbra Inc
Public float
$9.70B
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$1.40B
Fiscal year ending Dec 31, 2025
Net income
$178M
Fiscal year ending Dec 31, 2025
R&D spending
$89.8M
Fiscal year ending Dec 31, 2025
Cash
$254M
As of Sep 30, 2026
Long-term debt
Not reported
Shares outstanding
39.4M
As of Oct 14, 2026
Private placements (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
Company details
From the company's latest Form D.
- Legal name
- Penumbra Inc
- Headquarters
- Alameda, California
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other Health Care
- SEC filer
- CIK 1321732 ↗
Executives, directors and promoters
As listed on the latest Form D.
7 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
The 8 newest of 68 since 2015.
K262904 · Decided Oct 15, 2026 · 58 days after receipt
Device type: Peripheral Mechanical Thrombectomy With Aspiration (QEW) · Cardiology
K250690 · Decided Jun 10, 2026 · 460 days after receipt
Device type: Catheter, Thrombus Retriever (NRY) · Cardiology
K260599 · Decided Apr 24, 2026 · 59 days after receipt
Device type: Peripheral Mechanical Thrombectomy With Aspiration (QEW) · Cardiology
65 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT07749170 · 250 participants (planned) · Start Jun 26, 2026 · Primary completion Sep 2028
Device: Endovascular Thrombectomy · For: Acute Ischemic Stroke; Acute Ischemic Stroke (AIS) Related to a Distal Occlusion
Sites: Englewood, Colorado; New Haven, Connecticut; Lexington, Kentucky · 10 sites in all
NCT04798261 · 1,500 participants (planned) · Start Jun 25, 2021 · Primary completion Dec 2026
Device: Indigo Aspiration System · For: Pulmonary Embolism
Sites: Long Beach, California; Los Angeles, California; Orange, California · 79 sites in all
NCT05437055 · 216 participants · Start Aug 11, 2022 · Primary completion Sep 23, 2024
Device: Mechanical Thrombectomy (Penumbra System with Thunderbolt) · For: Acute Ischemic Stroke; Large Vessel Occlusion
Sites: Goodyear, Arizona; San Diego, California; Englewood, Colorado · 32 sites in all
28 more trials with a free account
Reports received
449
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
388
86% of reports
Injury reports
55
12% of reports
Death reports
6
1.3% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 39 | 6 | 0 | 0 |
| Jan 24 | 25 | 7 | 6 | 0 |
| Feb 24 | 21 | 8 | 5 | 0 |
| Mar 24 | 33 | 17 | 2 | 0 |
| Apr 24 | 42 | 10 | 1 | 0 |
| May 24 | 49 | 4 | 0 | 0 |
| Jun 24 | 19 | 3 | 0 | 0 |
| Jul 24 | 27 | 4 | 2 | 0 |
| Aug 24 | 34 | 4 | 0 | 0 |
| Sep 24 | 25 | 5 | 0 | 0 |
| Oct 24 | 28 | 9 | 2 | 0 |
| Nov 24 | 28 | 4 | 0 | 0 |
| Dec 24 | 30 | 2 | 1 | 0 |
| Jan 25 | 22 | 6 | 1 | 0 |
| Feb 25 | 30 | 10 | 1 | 0 |
| Mar 25 | 30 | 3 | 0 | 0 |
| Apr 25 | 33 | 12 | 4 | 0 |
| May 25 | 28 | 8 | 2 | 0 |
| Jun 25 | 35 | 10 | 3 | 0 |
| Jul 25 | 24 | 2 | 0 | 0 |
| Aug 25 | 30 | 5 | 3 | 0 |
| Sep 25 | 26 | 8 | 0 | 0 |
| Oct 25 | 34 | 8 | 0 | 0 |
| Nov 25 | 25 | 4 | 1 | 0 |
| Dec 25 | 36 | 6 | 0 | 0 |
| Jan 26 | 27 | 7 | 0 | 0 |
| Feb 26 | 21 | 2 | 3 | 0 |
| Mar 26 | 37 | 12 | 0 | 0 |
| Apr 26 | 49 | 1 | 0 | 0 |
| May 26 | 26 | 1 | 0 | 0 |
| Jun 26 | 39 | 2 | 0 | 0 |
| Jul 26 | 23 | 4 | 0 | 0 |
| Aug 26 | 36 | 2 | 1 | 0 |
| Sep 26 | 45 | 8 | 1 | 0 |
| Oct 26 | 24 | 6 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
6 more in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-3331-2026 · Started Jul 24, 2026 · Posted by FDA Sep 29, 2026
Reason given: Due to manufacturing issues reperfusion catheters may fracture.
Cause as FDA categorized it: Under Investigation by firm · Device type: Catheter, Thrombus Retriever (NRY)
- Penumbra System RED 68 Reperfusion Catheter REF: RED68KITOpen, Classified
Z-2770-2026 · Started Jun 3, 2026 · Posted by FDA Jul 21, 2026
Reason given: Due to manufacturing issues, reperfusion catheters may fractures
Cause as FDA categorized it: Under Investigation by firm · Device type: Catheter, Thrombus Retriever (NRY)
Z-0848-2021 · Started Dec 15, 2020 · Posted by FDA Jan 18, 2021
Reason given: The catheter may become susceptible to distal tip damage during use. Distal tip damage in conjunction with pressurization of contrast injection may result in potential vessel damage, and subsequent patient injury or death.
Cause as FDA categorized it: Process design · Device type: Catheter, Thrombus Retriever (NRY)
9 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.